Navigation Links
Eureka Therapeutics raises $21 million in series c to expand cancer immunotherapy pipeline
Date:9/23/2014

Eureka Therapeutics, Inc. announced today that the Company has secured $21 million in a Series C Financing. The new funding will be used to expand the Company's cancer immunotherapy pipeline and advance its lead programs to clinical development. New investor Yuan Capital led the round, with participation from Majuven and all existing major investors, including Acorn Campus Ventures, Suma Venture and Harbinger Venture Capital.

Eureka is engaged in the discovery and development of fully-human antibodies engineered to mimic the functions of a T cell receptor, a key component of the immune system. These therapeutic antibodies are designed to recognize proteins residing inside of cancer cells, and mobilize a patient's immune system to recognize and kill the diseased cell.

"This new funding will allow us to expand and advance our drug pipeline, as well as explore the synergistic effects of our drug candidates with other immunotherapies and immune modulators," said Cheng Liu, PhD, President and CEO of Eureka Therapeutics. "This moves us closer to our goal of providing cancer patients with safer and more effective treatments through novel immunotherapies."

"We are pleased to have the continued confidence and support of our existing investors, and we welcome our new investors," added Dr. Liu.

Earlier this year, the Company announced a license agreement with Novartis for the development and commercialization of ESK1, a preclinical-stage monoclonal antibody for the treatment of leukemia and other cancers. The antibody, targeting the intracellular protein WT1, was developed under a collaborative effort between Eureka Therapeutics and Memorial Sloan-Kettering Cancer Center.


'/>"/>

Contact: Elisa Pan
admin@eurekainc.com
510-654-7045
Eureka Therapeutics, Inc.

Source:Eurekalert

Page: 1

Related biology news :

1. EUREKA grant to fund development of new optogenetic technique for mapping neural networks at UMMS
2. Study shows Hera Therapeutics compound combats HPV types that cause most cervical cancer
3. Human Longevity, Inc. and Celgene Cellular Therapeutics Sign License Agreement to Develop and Commercialize Placental Stem Cell Population, PSC-100 for Multiple Therapeutic Applications
4. Splice-switching oligonucleotide therapeutics is new method for editing gene transcript
5. Industry group release testing recommendations for oligonucleotide-based therapeutics
6. Nanomerics, UCL, H Lundbeck & Exeter University to research new brain therapeutics
7. Next-generation glaucoma therapeutics hold considerable promise
8. FASEB announces 2014 SRC: Translational Neuroimmunology: From Mechanisms to Therapeutics
9. Emerging class of therapeutics represents a coming wave for developers and manufacturers
10. Natura Therapeutics product shown to improve decision making skills in older adults
11. Arcturus Therapeutics Raises $5 Million in Series A Funding to Maintain its Momentum in Nominating Lead Clinical Candidate in 2014
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/1/2018)... ... 01, 2018 , ... VSee, the telehealth system for NASA ... monitoring technology providing real-time information on individual patient dialysis tolerance, are partnering to ... a telehealth visit without the use of traditional medical devices. , One of ...
(Date:9/29/2018)... (PRWEB) , ... September 29, 2018 , ... ... chief officers of Life Science companies. The in-person briefings are expected to transform ... data science is bringing to the U.S. healthcare market—especially to individuals, employers, and ...
(Date:9/28/2018)... DENVILLE, N.J. (PRWEB) , ... ... ... leading global provider for complete solutions for sample preparation and epigenetics research, ... late last year from the Research Center of Molecular Medicine of the ...
Breaking Biology News(10 mins):
(Date:9/27/2018)... EWING, N.J. (PRWEB) , ... September 26, 2018 ... ... and DNA testing are way ahead of their primary care physicians, according to ... , For this study, patients and doctors were asked about consumer adoption of ...
(Date:9/27/2018)... , ... September 27, 2018 , ... ... City, Everwell Health Solutions and SureAdhere Mobile Technology, Inc. announced they will formally ... monitoring in the battle against tuberculosis (TB) and other diseases. These two social ...
(Date:9/22/2018)... ... September 20, 2018 , ... ... a strategic venture. The synergistic combination of Predicine’s GeneRADAR molecular insights platform ... biomarker profiling to empower clinical trials in the immuno-oncology (IO) space. , ...
(Date:9/15/2018)... ... September 14, 2018 , ... Next-generation genomic sequencing is ... with new technologies, challenges remain. In the past, the sheer size of genomics data ... Cloud is a new data ecosystem developed to advance cures by reducing the technological ...
Breaking Biology Technology: